Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/1999
11/25/1999WO1999059616A1 Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
11/25/1999WO1999059612A1 Method for the treatment of gastroesophageal reflux disease
11/25/1999WO1999059608A2 Osteoporosis treatment
11/25/1999WO1999059606A1 Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process
11/25/1999WO1999059603A1 Remedies for joint diseases bound to hyaluronic acid
11/25/1999WO1999059602A1 Novel pharmaceutical composition for use in emergency treatment and preparation method thereof
11/25/1999WO1999059601A1 Use of a nucleic acid-binding chemotherapeutic agent, and a pharmaceutical composition
11/25/1999WO1999059600A1 Synergistic composition for use in the treatment of cancer
11/25/1999WO1999059599A1 Edelfosin for the treatment of brain tumours
11/25/1999WO1999059598A1 Use of tricyclic antidepressants for local analgesia
11/25/1999WO1999059597A1 Ionophore containing composition for modulating amyloidosis
11/25/1999WO1999059596A1 Glucocorticoid receptor antagonists for the treatment of dementia
11/25/1999WO1999059595A1 Progesterone treatment of cancer
11/25/1999WO1999059594A1 Potassium channel agonists
11/25/1999WO1999059593A1 Combination therapy for treatment of depression
11/25/1999WO1999059592A1 ANTIMALARIAL ACTIVITY OF β-CARBOLINE ALKALOIDS
11/25/1999WO1999059591A1 Pyrazinone thrombin inhibitors
11/25/1999WO1999059590A1 (+)-hydroxyrisperidone compositions and methods
11/25/1999WO1999059589A1 (-)-hydroxyrisperidone compositions and methods
11/25/1999WO1999059588A1 Medicinal composition reduced in bitterness
11/25/1999WO1999059587A1 Anti-viral compounds
11/25/1999WO1999059586A1 Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
11/25/1999WO1999059585A1 Compositions for the treatment of hiv and other viral infections
11/25/1999WO1999059584A1 Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
11/25/1999WO1999059583A1 Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
11/25/1999WO1999059582A1 Amide therapeutics for the treatment of inflammatory bowel disease
11/25/1999WO1999059581A1 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens
11/25/1999WO1999059579A1 Furan nitrone therapeutics for the treatment of inflammatory bowel disease
11/25/1999WO1999059578A1 Triterpene compositions and methods for use thereof
11/25/1999WO1999059577A1 Topical application of muscarinic analgesic drugs such as neostigmine
11/25/1999WO1999059576A1 Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
11/25/1999WO1999059575A1 Compositions comprising organic mono- or dinitrate for treating impotence
11/25/1999WO1999059574A1 A method for stimulation of defensin production by exposure to isoleucin
11/25/1999WO1999059573A1 Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
11/25/1999WO1999059572A1 Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
11/25/1999WO1999059571A1 Use of amyloid inhibitors for modulating neuronal cell death
11/25/1999WO1999059570A1 Protease inhibitors
11/25/1999WO1999059569A1 Benzamide therapeutics for the treatment of inflammatory bowel disease
11/25/1999WO1999059568A1 Hydroxamic acid derivatives as antibacterials
11/25/1999WO1999059567A1 INHIBITION OF IgA PRODUCTION
11/25/1999WO1999059566A1 Use of nitric oxide synthase inhibitors in the manufacture of a medicament for the prophylaxis or treatment of bacterial infection
11/25/1999WO1999059565A1 Novel compositions
11/25/1999WO1999059564A1 Pharmaceutical composition comprising d-chiro-inositol for improving insulin sensitivity and glucose metabolism
11/25/1999WO1999059563A2 Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease
11/25/1999WO1999059562A2 Method of treating or preventing abnormal cardiac cell growth by inhibiting the 12-lipoxygenase pathway
11/25/1999WO1999059561A2 Resveratrol inhibition of myeloperoxidase
11/25/1999WO1999059560A1 Glucose transport modulators and uses therefor
11/25/1999WO1999059558A1 Transdermal therapeutic system containing pergolide
11/25/1999WO1999059557A1 Multiparticulate pharmaceutical form with programmed and timed release and preparation method
11/25/1999WO1999059553A1 Effervescent preparations
11/25/1999WO1999059551A1 Pharmaceutical preparation containing levothyroxine sodium
11/25/1999WO1999059550A1 Novel particulate formulations
11/25/1999WO1999059548A1 Controlled drug delivery system using the conjugation of drug to biodegradable polyester
11/25/1999WO1999059544A2 Orally disintegrable tablets
11/25/1999WO1999059526A2 Protease inhibitors
11/25/1999WO1999059525A2 Broad spectrum microbicidal and spermicidal compositions, devices, and methods
11/25/1999WO1999059524A2 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of neurogenic inflammation
11/25/1999WO1999059499A2 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
11/25/1999WO1999059423A1 Oil and fat composition containing phytosterol
11/25/1999WO1999050249A3 Pyrimidines and triazines as integrin antagonists
11/25/1999WO1999049859A9 Dfmo and sulindac combination in cancer chemoprevention
11/25/1999WO1999049844A3 Method for producing transdermal therapeutic systems by using basic alkali metal salts for converting active agent salts into free bases
11/25/1999WO1999048523A3 Antagonists of the inflammatory mediator oncostatin m (osm)
11/25/1999WO1999048507A3 Steroidal saponins for treating alzheimer's disease
11/25/1999WO1999048484A3 Use of cabergoline in the treatment of restless legs syndrome
11/25/1999WO1999047925A3 Methods and compositions for diagnosis of rheumatoid arthritis
11/25/1999WO1999047545A3 Inhibitors of caspases
11/25/1999WO1999047517A8 Novel heterocyclic compounds
11/25/1999WO1999047101A3 Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
11/25/1999WO1999044595A3 Pharmaceutical compositions for ulcer
11/25/1999WO1999043832A3 Human proteinase molecules
11/25/1999WO1999042834A3 Treating cancer
11/25/1999WO1999042602A3 Fermentative preparation process for cytostatics and crystal forms thereof
11/25/1999WO1999040068A3 2-aminoquinoline derivatives having d4-agonistic activity
11/25/1999WO1999040067A3 Benzisoxazole derivatives having d4-antagonistic activity
11/25/1999WO1999039740A9 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
11/25/1999WO1999005527A3 Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens
11/25/1999WO1998041226A9 Pharmaceutical combined preparations containing erythropoietin and iron preparations
11/25/1999WO1998018500A8 Improvements in or relating to diagnostic/therapeutic agents
11/25/1999DE19922287A1 Cosmetic, dermatological, pharmaceutical, dietetic or food compositions, e.g. for improving skin condition, comprise flavonoid esters
11/25/1999DE19844079A1 New four-layer transdermal system
11/25/1999DE19822955A1 Veterinary medicament for treating glaucoma
11/25/1999DE19822954A1 Ki-67 gene antisense oligonucleotide
11/25/1999DE19822549A1 New suppository formulations for acid-labile drugs
11/25/1999DE19822509A1 Use of edelfosin for treatment of brain tumors, especially by oral administration
11/25/1999DE19820801A1 Oral dosage form for gatifloxacin, providing reproducible decomposition time and drug release
11/25/1999DE19819012A1 Feuersichere, nicht explosionsfähige, Nitroglycerin und wasserfreie Lactose enthaltende Feststoffmischungen Fire-proof, non-explosive, containing nitroglycerin and anhydrous lactose mixtures of solids
11/25/1999CA2709441A1 Triterpene compositions and methods for use thereof
11/25/1999CA2587022A1 Orally disintegrable tablets
11/25/1999CA2345917A1 Antitumour 1,5-diazaanthraquinones
11/25/1999CA2333310A1 Use of tricyclic antidepressants for local analgesia
11/25/1999CA2333274A1 Thermally stable trimetrexates and processes for producing the same
11/25/1999CA2333203A1 Methods for modulating neuronal cell death
11/25/1999CA2333193A1 Pharmaceutical preparation
11/25/1999CA2333190A1 Furan nitrone therapeutics for the treatment of inflammatory bowel disease
11/25/1999CA2333103A1 Method of locking 1.alpha.-oh of vitamin d compounds in axial orientation
11/25/1999CA2333087A1 Compositions and methods for the pulmonary delivery of nucleic acids
11/25/1999CA2332961A1 A method for stimulation of defensin production by exposure to isoleucine
11/25/1999CA2332802A1 Conjugate of therapeutic agent for joint disease and hyaluronic acid
11/25/1999CA2332774A1 Method for the treatment of gastroesophageal reflux disease
1 ... 6405 6406 6407 6408 6409 6410 6411 6412 6413 6414 6415 6416 6417 6418 6419 6420 6421 6422 6423 6424 6425 ... 7860